NCT03546231 Characteristics and Prognosis of Moderate or Severe Tricuspid Regurgitation
| NCT ID | NCT03546231 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Universitaire, Amiens |
| Condition | Tricuspid Valve Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 400 participants |
| Start Date | 2018-03-15 |
| Primary Completion | 2026-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 400 participants in total. It began in 2018-03-15 with a primary completion date of 2026-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The tricuspid valve : its evaluation is relatively difficult in echocardiography and the management of tricuspid valve diseases remains poorly codified.
Eligibility Criteria
Inclusion Criteria: * Age \>18 ans * inclusion criteria: moderate or severe tricuspid regurgitation * exclusion criteria: Refusal to participate/ prior surgery of the tricuspid valve
Contact & Investigator
Christophe TRIBOUILLOY, Pr
PRINCIPAL INVESTIGATOR
CHU AMIENS-PICARDIE
Frequently Asked Questions
Who can join the NCT03546231 clinical trial?
This trial is open to participants of all sexes, aged 18 Months or older, studying Tricuspid Valve Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03546231 currently recruiting?
Yes, NCT03546231 is actively recruiting participants. Contact the research team at Tribouilloy.Christophe@chu-amiens.fr for enrollment information.
Where is the NCT03546231 trial being conducted?
This trial is being conducted at Amiens, France.
Who is sponsoring the NCT03546231 clinical trial?
NCT03546231 is sponsored by Centre Hospitalier Universitaire, Amiens. The principal investigator is Christophe TRIBOUILLOY, Pr at CHU AMIENS-PICARDIE. The trial plans to enroll 400 participants.